- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04571970
RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)
November 17, 2023 updated by: REGENXBIO Inc.
A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of RGX-121 in Children 5 Years of Age and Older With MPS II (Hunter Syndrome)
RGX-121 is a gene therapy which is designed to deliver a functional copy of the iduronate-2-sulfatase (IDS) gene to the central nervous system.
This study is a phase I/II study to determine whether RGX-121 is safe, well tolerated, and potentially effective in children five years of age and over who have severe MPS II.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
MPS II is a rare X-linked recessive genetic disease caused by mutations in the iduronate-2-sulfatase (IDS) gene.
Enzyme replacement therapy (ERT) with recombinant idursulfase (ELAPRASE®) is the only approved product for the treatment of Hunter syndrome; however, ERT as currently administered does not cross the blood brain barrier and is therefore unable to address the unmet need in MPS II patients with CNS (neurocognition and behavior) involvement.
RGX-121 is designed to deliver a healthy gene to cells in the CNS and iduronate-2-sulfatase (I2S) may then be secreted by transduced cells which may cross-correct non-transduced cells by taking up the functional enzyme.
This is a Phase I/II, multicenter, open-label, single arm study of RGX-121.
Approximately 6 children (≥ 5 years to < 18 years of age) who have severe (neuronopathic) MPS II could be enrolled into a single dose cohort and will receive a single dose of RGX-121 administered by IC or ICV injection.
Safety will be the primary focus for the initial 24 weeks after treatment (primary study period).
Following completion of the primary study period, participants will continue to be assessed (safety and efficacy) for up to a total of 104 weeks following treatment with RGX-121.
Study Type
Interventional
Enrollment (Estimated)
6
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patient Advocacy
- Phone Number: (866) 860-0117
- Email: MPSII@regenxbio.com
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H4A 3J1
- McGill University Heath Center
-
-
-
-
California
-
Oakland, California, United States, 94609
- University of California San Francisco, Benioff Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Meets any of the following criteria:
- Has a documented diagnosis of MPS II AND a neurocognitive testing score ≤ 1 ½ standard deviation (SD) from the test normative mean (BSID-III: 77 and MSEL Visual Reception: 35), OR
- Has a documented diagnosis of MPS II AND has a decline of ≥ 1 standard deviation on serial neurocognitive testing administered between 3 to 36 months apart (BSID-III Cognitive or MSEL Visual Reception), OR
- Has a relative clinically diagnosed with neuronopathic MPS II who has the same IDS mutation as the participant AND the participant in the opinion of a geneticist has inherited a neuronopathic form of MPS II, OR
- Has documented mutation(s) in IDS that in the opinion of a geneticist is known to result in a neuronopathic phenotype AND in the opinion of a clinician has a neuronopathic form of MPS II
Exclusion Criteria:
- Has contraindications for intracisternal injection, intracerebroventricular injection, or lumbar puncture
- Has contraindications for immunosuppressive therapy
- Has any neurocognitive deficit not attributable to MPS II or diagnosis of a neuropsychiatric condition
- Has had prior treatment with an AAV-based gene therapy product
- If receiving ELAPRASE® via intrathecal (IT) administration, must agree to discontinue IT idursulfase for the duration of the study
- Has experienced a serious hypersensitivity reaction to intravenous (IV) ELAPRASE®
- Is currently failing to respond to idursulfase (ELAPRASE®) IV due to neutralizing anti-idursulfase antibodies
- Has received any investigational product within 30 days of Day 1 or 5 half-lives before signing of the ICF, whichever is longer
- Has a platelet count <100,000 per microliter (µL), absolute neutrophil count <1.0 × 103/µL, or aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN) or total bilirubin >1.5 × ULN at screening unless the participant has a previously known history of Gilbert's syndrome
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
6.5 × 10^10 GC/g brain mass of RGX-121
|
Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events and serious adverse events
Time Frame: 24 Weeks
|
Number of participants with treatment-related adverse events and serious adverse events as assessed by CTCAE (Version 5.0)
|
24 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events and serious adverse events
Time Frame: 104 Weeks
|
Number of participants with treatment-related adverse events and serious adverse events as assessed by CTCAE (Version 5.0)
|
104 Weeks
|
Biomarkers
Time Frame: Baseline, Week 1, Week 2, Week 4, Week 12, Week 24, Week 38, Week 52, Week 64, Week 78, Week 104
|
Change from baseline in Glycosaminoglycan levels (ng/mL)
|
Baseline, Week 1, Week 2, Week 4, Week 12, Week 24, Week 38, Week 52, Week 64, Week 78, Week 104
|
Biomarkers
Time Frame: Baseline, Week 1, Week 2, Week 4, Week 12, Week 24, Week 38, Week 52, Week 64, Week 78, Week 104
|
Change from baseline in iduronate-2-sulfatase activity
|
Baseline, Week 1, Week 2, Week 4, Week 12, Week 24, Week 38, Week 52, Week 64, Week 78, Week 104
|
Change in neurodevelopmental parameters
Time Frame: Baseline, Week 52, Week 104
|
Change from baseline in neurodevelopmental parameters of cognitive function as measured by the Bayley Scales of Infant and Toddler Development, 3rd Edition (BSID-III)
|
Baseline, Week 52, Week 104
|
Change in neurodevelopmental parameters
Time Frame: Baseline, Week 52, Week 104
|
Change from baseline in neurodevelopmental parameters of cognitive function as measured by the Mullen Scales of Early Learning (MSEL)
|
Baseline, Week 52, Week 104
|
Change in neurodevelopmental parameters
Time Frame: Baseline, Week 24, Week 52, Week 78, Week 104
|
Change from baseline in neurodevelopmental parameters as measured by the Vineland Adaptive Behavior Scales, 2nd Edition (VABS-II), Comprehensive Interview Form
|
Baseline, Week 24, Week 52, Week 78, Week 104
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 11, 2021
Primary Completion (Estimated)
May 1, 2024
Study Completion (Estimated)
November 1, 2025
Study Registration Dates
First Submitted
September 23, 2020
First Submitted That Met QC Criteria
September 30, 2020
First Posted (Actual)
October 1, 2020
Study Record Updates
Last Update Posted (Actual)
November 18, 2023
Last Update Submitted That Met QC Criteria
November 17, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Connective Tissue Diseases
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Mucinoses
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Mucopolysaccharidosis II
- Mucopolysaccharidoses
Other Study ID Numbers
- RGX-121-1102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mucopolysaccharidosis Type II (MPS II)
-
University of ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedKrabbe Disease | Mucopolysaccharidosis Type II (MPS II) | Mucopolysaccharidosis Type I (MPS I) | Mucopolysaccharidosis Type III (MPS III) | Mucopolysaccharidosis Type VI (MPS VI)United States
-
REGENXBIO Inc.Active, not recruitingMucopolysaccharidosis Type II (MPS II)United States, Brazil
-
TakedaCompletedMucopolysaccharidosis (MPS)Brazil
-
ShireCompletedHunter Syndrome | Mucopolysaccharidosis II (MPS II)United States, France, United Kingdom, Germany, Sweden, Spain, Brazil, Canada, Italy, Romania
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VI | Mucopolysaccharidosis Type IV | Mucopolysaccharidosis Type VIIUnited States, Canada
-
Allievex CorporationCompletedMucopolysaccharidosis Type IIIB | Mucopolysaccharidosis Type 3 B | MPS III B | MPS 3 BUnited States, Spain, Turkey, Taiwan, Australia, Colombia, Germany, United Kingdom
-
Lundquist Institute for Biomedical Innovation at...CompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Mucopolysaccharidosis Type VIUnited States
-
SanofiCompletedPompe Disease | Mucopolysaccharidosis Type I (MPS I)Italy
-
Sangamo TherapeuticsTerminatedMucopolysaccharidosis II | MPS IIUnited States
-
University Hospital HeidelbergCompletedMucopolysaccharidosis Type I | Mucopolysaccharidosis Type II | Coping Behavior | Mucopolysaccharidosis Type III | Behavior DisordersGermany
Clinical Trials on RGX-121
-
REGENXBIO Inc.Active, not recruitingMucopolysaccharidosis Type II (MPS II)United States, Brazil
-
AbbVieCompletedWet Macular Degeneration | Neovascular Age-related Macular Degeneration | Wet Age-related Macular DegenerationUnited States
-
AbbVieAbbVieRecruiting
-
REGENXBIO Inc.RecruitingDuchenne Muscular DystrophyUnited States
-
REGENXBIO Inc.Active, not recruitingHurler Syndrome | Hurler-Scheie Syndrome | Mucopolysaccharidosis Type I (MPS I)United States, Brazil, Israel
-
Valeant PharmaceuticalsUnknown
-
AbbVieAbbVieEnrolling by invitationWet Macular Degeneration | Neovascular Age-related Macular DegenerationUnited States
-
REGENXBIO Inc.CompletedNeovascular Age-related Macular Degeneration | Wet Age-related Macular DegenerationUnited States
-
Valeant PharmaceuticalsUnknown
-
Vertex Pharmaceuticals IncorporatedActive, not recruitingCystic FibrosisUnited States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom